知镜 Cognispect · 医学文献与研究工作台

Recent advances in antioxidant nanozymes for the treatment of inflammatory bowel disease.

Shen Z, Rui S, Zhang J, Feng S, Liu B, Liu Z, Wang S, Guo J, Zhao Q.
Nanomedicine : nanotechnology, biology, and medicine · 2026-10-03 · PMID 42829151

文献摘要

Inflammatory bowel disease (IBD) refers to a group of chronic, nonspecific gastrointestinal disorders that impose a significant global health burden. Conventional therapies are frequently hindered by severe off-target toxicities and compromised efficacy within the dynamically changing intestinal microenvironment. Recently, nanozymes have emerged as a revolutionary therapeutic paradigm for IBD, offering potent reactive oxygen species (ROS) scavenging and profound immunoregulatory capabilities. Herein, we summarize the latest advances in nanozyme-based IBD therapies. Firstly, we categorize the diverse nanozyme platforms utilized in IBD therapy, spanning metal-based, metal-organic framework (MOF)-based, organic, and carbon-based materials. Subsequently, we highlight how advanced rational design strategies, including surface modification, electronic structure regulation, defect engineering, and atomic doping, orchestrate complex bio-modulatory effects, encompassing mitochondrial homeostasis restoration, inflammatory signaling pathway modulation, programmed cell death (PCD) intervention, and intestinal barrier regeneration. Furthermore, to overcome biopharmaceutical bottlenecks, we provide an overview of nanozyme-based intelligent delivery platforms tailored for the inflamed gut, covering endogenous/exogenous stimuli-responsive, biomimetic, and microbiota-mediated systems. Finally, we critically evaluate the impending translational challenges and future perspectives of nanozyme-based nanomedicines, providing a rigorous roadmap for the development of spatiotemporally controlled, precision gastroenterology therapies.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。